格隆汇2月20日丨华东医药(000963.SZ)于2023年2月15日14:30-16:00；2月16日11:00-11:40、14:00-15:00接受机构现场调研时表示，Sinclair目前医美收入主要来源于Ellansé®、MaiLi系列新型高端玻尿酸、Lanluma®胶原蛋白刺激剂等核心注射类产品，旗下HighTech公司的Cooltech Define、Viora公司V系列等能量源设备产品也处在快速增长期。Sinclair去年克服了海外通胀引起的运营成本、人工成本上涨的影响，整体经营持续向好，盈利状况也逐步改善，今年亦有望实现较好增长。
Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.
